These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26474861)

  • 21. Rationale and evidence for extended infusion of piperacillin-tazobactam.
    Kaufman SE; Donnell RW; Hickey WS
    Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
    Falagas ME; Tansarli GS; Ikawa K; Vardakas KZ
    Clin Infect Dis; 2013 Jan; 56(2):272-82. PubMed ID: 23074314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
    Pournaras S; Ikonomidis A; Neou E; Kantzanou M; Maniatis AN; Tsakris A
    J Antimicrob Chemother; 2008 Mar; 61(3):757-8. PubMed ID: 18199562
    [No Abstract]   [Full Text] [Related]  

  • 24. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
    Graham DR; Lucasti C; Malafaia O; Nichols RL; Holtom P; Perez NQ; McAdams A; Woods GL; Ceesay TP; Gesser R
    Clin Infect Dis; 2002 Jun; 34(11):1460-8. PubMed ID: 12015692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
    Yusuf E; Spapen H; Piérard D
    J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
    Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
    Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.
    Zelenitsky S; Nash J; Weber Z; Iacovides H; Ariano R
    J Chemother; 2016 Oct; 28(5):390-4. PubMed ID: 27077931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa].
    Djordjević Z; Gajović O; Mijailović Z; Ilić A; Stolić R
    Srp Arh Celok Lek; 2013; 141(9-10):640-7. PubMed ID: 24364227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
    Lü Y; Yan Z; Wang DH; Dong WL; Yang Y; Xia R
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
    Xu ZR; Ran XW; Xian Y; Yan XD; Yuan GY; Mu SM; Shen JF; Zhang BS; Gan WJ; Wang J
    J Antimicrob Chemother; 2016 Jun; 71(6):1688-96. PubMed ID: 26888908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
    Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
    Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S; Pai MP; Lodise TP
    J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.
    Lorente L; Jiménez A; Martín MM; Iribarren JL; Jiménez JJ; Mora ML
    Int J Antimicrob Agents; 2009 May; 33(5):464-8. PubMed ID: 19150225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.
    Harris AD; Perencevich E; Roghmann MC; Morris G; Kaye KS; Johnson JA
    Antimicrob Agents Chemother; 2002 Mar; 46(3):854-8. PubMed ID: 11850272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.
    Siami FS; LaFleur BJ; Siami GA
    Clin Ther; 2002 Jan; 24(1):59-72. PubMed ID: 11833836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.